Success Metrics

Clinical Success Rate
64.7%

Based on 11 completed trials

Completion Rate
65%(11/17)
Active Trials
16(36%)
Results Posted
73%(8 trials)
Terminated
6(13%)

Phase Distribution

Ph not_applicable
1
2%
Ph phase_1
4
9%
Ph phase_2
25
56%
Ph phase_3
10
22%
Ph phase_4
1
2%

Phase Distribution

4

Early Stage

25

Mid Stage

11

Late Stage

Phase Distribution41 total trials
Phase 1Safety & dosage
4(9.8%)
Phase 2Efficacy & side effects
25(61.0%)
Phase 3Large-scale testing
10(24.4%)
Phase 4Post-market surveillance
1(2.4%)
N/ANon-phased studies
1(2.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

57.9%

11 of 19 finished

Non-Completion Rate

42.1%

8 ended early

Currently Active

16

trials recruiting

Total Trials

45

all time

Status Distribution
Active(18)
Completed(11)
Terminated(8)
Other(8)

Detailed Status

Recruiting12
Completed11
unknown8
Terminated6
Active, not recruiting4
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
45
Active
16
Success Rate
64.7%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (9.8%)
Phase 225 (61.0%)
Phase 310 (24.4%)
Phase 41 (2.4%)
N/A1 (2.4%)

Trials by Status

completed1124%
unknown818%
terminated613%
active_not_recruiting49%
withdrawn24%
not_yet_recruiting24%
recruiting1227%

Recent Activity

Clinical Trials (45)

Showing 20 of 45 trialsScroll for more
NCT06563479Phase 3

A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer

Recruiting
NCT06984861Phase 2

A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer

Recruiting
NCT05526924Phase 1

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Recruiting
NCT05894083Phase 2

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

Recruiting
NCT03322995Phase 2

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

Recruiting
NCT05417386Phase 1

FOLFIRINOX + NIS793 in Pancreatic Cancer

Terminated
NCT04305613

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

Active Not Recruiting
NCT06191133Phase 1

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Recruiting
NCT03110926Phase 2

Induction Chemotherapy for Locally Advanced Esophageal Cancer

Active Not Recruiting
NCT06719362Phase 1

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Recruiting
NCT04821765Phase 2

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Completed
NCT06926543Phase 3

Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy

Recruiting
NCT02867865Phase 2

Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers

Active Not Recruiting
NCT03838263Phase 2

Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

Completed
NCT05546411Phase 2

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Terminated
NCT06385717

Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer

Recruiting
NCT05905315Phase 2

Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC

Recruiting
NCT02446093Phase 2

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Active Not Recruiting
NCT05492123Phase 2

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Recruiting
NCT02207439Phase 2

Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

Completed

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
45